ATE426389T1 - Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische - Google Patents

Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische

Info

Publication number
ATE426389T1
ATE426389T1 AT02804079T AT02804079T ATE426389T1 AT E426389 T1 ATE426389 T1 AT E426389T1 AT 02804079 T AT02804079 T AT 02804079T AT 02804079 T AT02804079 T AT 02804079T AT E426389 T1 ATE426389 T1 AT E426389T1
Authority
AT
Austria
Prior art keywords
theaflavin
gallate
digallate
mixtures
production
Prior art date
Application number
AT02804079T
Other languages
English (en)
Inventor
Jian Zhao
Rui Zhou
Hu Room Chen
Original Assignee
Nashai Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNB021115125A external-priority patent/CN1156276C/zh
Application filed by Nashai Biotech Llc filed Critical Nashai Biotech Llc
Application granted granted Critical
Publication of ATE426389T1 publication Critical patent/ATE426389T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT02804079T 2001-11-28 2002-11-27 Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische ATE426389T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33351501P 2001-11-28 2001-11-28
CNB021115125A CN1156276C (zh) 2002-04-26 2002-04-26 茶黄素的新用途
US41357602P 2002-09-24 2002-09-24

Publications (1)

Publication Number Publication Date
ATE426389T1 true ATE426389T1 (de) 2009-04-15

Family

ID=27178819

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804079T ATE426389T1 (de) 2001-11-28 2002-11-27 Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische

Country Status (10)

Country Link
EP (1) EP1460999B1 (de)
JP (1) JP2005523242A (de)
KR (1) KR20080052675A (de)
AT (1) ATE426389T1 (de)
AU (1) AU2002365415C1 (de)
CA (1) CA2467664A1 (de)
DE (1) DE60231747D1 (de)
MX (1) MXPA04005113A (de)
NZ (2) NZ569389A (de)
WO (1) WO2003045328A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100389778C (zh) * 2004-02-17 2008-05-28 三得利株式会社 含有高分子多酚组分的脂肪酶活性抑制剂、茶提取物及其制造方法
JP5242885B2 (ja) * 2004-05-20 2013-07-24 株式会社 伊藤園 筋肉内ａｍｐｋ活性化剤
WO2006004114A1 (ja) * 2004-07-05 2006-01-12 Suntory Limited リパーゼ阻害剤
JP4880965B2 (ja) * 2005-10-03 2012-02-22 株式会社ヤクルト本社 抗脂肪性薬剤
US20090156662A1 (en) 2006-04-26 2009-06-18 Ito En, Ltd. Fat Absorption Inhibitor
JP5441046B2 (ja) * 2006-05-01 2014-03-12 国立大学法人 筑波大学 脂肪肝の予防および／または治療剤
TW201000019A (en) * 2008-03-28 2010-01-01 Shizuoka Prefectural University Corp Manufacturing method for theaflavins, using raw tea leaves
JP2010095478A (ja) * 2008-10-17 2010-04-30 Ito En Ltd 体脂肪蓄積抑制剤及び飲食品
JP2010095477A (ja) * 2008-10-17 2010-04-30 Ito En Ltd リパーゼ阻害剤
JP5614674B2 (ja) * 2009-09-18 2014-10-29 万壽美 竹元 生活習慣病予防及び改善剤
JP2012072084A (ja) * 2010-09-29 2012-04-12 Kracie Home Products Ltd エラスターゼ阻害剤並びにそれを含有する化粧品組成物及び医薬品組成物
CN103103227A (zh) * 2013-01-18 2013-05-15 徐州医学院 一种具有α-葡萄糖苷酶抑制作用的茶多酚氧化聚合物的制备工艺
JP6478368B2 (ja) * 2013-12-26 2019-03-06 大塚食品株式会社 テアフラビン類の製造方法、及びテアフラビン類を含む飲料
WO2015146505A1 (ja) * 2014-03-27 2015-10-01 焼津水産化学工業株式会社 口腔内細菌増殖抑制剤
JP6639388B2 (ja) * 2014-06-27 2020-02-05 株式会社Ｎｂｃメッシュテック テアフラビン類の合成用触媒およびテアフラビン類の合成方法
CN106511362B (zh) * 2015-09-15 2020-11-17 广东省人民医院 一种防治动脉粥样硬化的茶多酚组合物
JP6778506B2 (ja) * 2016-04-21 2020-11-04 焼津水産化学工業株式会社 機能性食品組成物
WO2020218755A1 (ko) * 2019-04-25 2020-10-29 ㈜아모레퍼시픽 테아플라빈을 포함하는 지방세포 분화 촉진용 조성물
CN114533723A (zh) * 2022-01-19 2022-05-27 湖南农业大学 一种调节骨骼肌糖代谢与线粒体生成的膳食营养补充剂及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2975057A (en) * 1958-05-23 1961-03-14 Lipton Inc Thomas J Process for converting green tea extract
CA995512A (en) * 1972-01-31 1976-08-24 Gary W. Sanderson Tea
JPS63214183A (ja) * 1987-03-03 1988-09-06 Mitsui Norin Kk アンジオテンシン１変換酵素阻害剤
JP3018013B2 (ja) * 1989-10-19 2000-03-13 三井農林株式会社 α―アミラーゼ活性阻害剤
US5318986A (en) * 1989-10-19 1994-06-07 Mitsui Norin Co., Ltd. Method of inhibiting the activity of α-amylase
CN1035660C (zh) * 1993-01-01 1997-08-20 江西省绿色工业(集团)公司 茶色素及其生产方法
JP4127863B2 (ja) * 1993-03-04 2008-07-30 太陽化学株式会社 腸内環境改善組成物
ATE199118T1 (de) * 1995-09-04 2001-02-15 Unilever Nv Verfahren zur farbvertiefung in nahrungsmitteln auf teebasis
DE19627344A1 (de) * 1996-07-01 1998-01-08 Vitasyn Gmbh Entwicklung & Ver Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenolverbindungen
JPH1132725A (ja) * 1997-07-24 1999-02-09 Mitsui Norin Kk 流動食
JP2000327572A (ja) * 1999-05-18 2000-11-28 Mitsui Norin Co Ltd スクアレンエポキシダーゼ阻害剤
CN1328092A (zh) * 2000-06-08 2001-12-26 陈虎 一种新的提取茶色素的方法及其在高血脂方面的应用

Also Published As

Publication number Publication date
EP1460999B1 (de) 2009-03-25
WO2003045328A2 (en) 2003-06-05
JP2005523242A (ja) 2005-08-04
EP1460999A4 (de) 2005-03-09
WO2003045328A3 (en) 2003-10-09
AU2002365415C1 (en) 2008-12-11
AU2002365415A1 (en) 2003-06-10
KR20080052675A (ko) 2008-06-11
NZ533190A (en) 2008-07-31
AU2002365415B2 (en) 2008-04-10
CA2467664A1 (en) 2003-06-05
DE60231747D1 (de) 2009-05-07
EP1460999A2 (de) 2004-09-29
MXPA04005113A (es) 2005-04-29
NZ569389A (en) 2010-01-29

Similar Documents

Publication Publication Date Title
ATE426389T1 (de) Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische
WO2004112715A3 (en) Methods of making and using theaflavin,theaflavin-3-gallate, theaflavin-3’-gallate and theaflavin 3,3’ - digallate and mixtures thereof
BG66103B1 (bg) Кондензирани пиролокарбазоли
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
IL110031A0 (en) Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them
PL348237A1 (en) Fused 1,2,4-thiadiazine derivatives, their preparation and use
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
ES2142570T3 (es) Bisesteres de acido alqu(en)ildicarboxilico, su empleo, asi como procedimientos para su obtencion.
WO2004043954A3 (en) Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same
ATE471924T1 (de) 3-alkyl-5,5',6,6',7,7',8,8'-octahydro-2,2'- binaphthole und 3,3'-dialkyl-5,5',6,6',7,7',8,8'- octahydro-2,2'-binaphthole, sowie verfahren zur ihrer herstellung
WO2000021910A3 (en) 1,2-disubstituted cyclopropanes
WO2005063764A3 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TW200420294A (en) Methods of making and using theaflavin, thealflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3, 3'-digallate and mixtures thereof
HK1018265A1 (en) Piperazino derivatives as neurokinin antagonists
DE69927602D1 (de) Verfahren zur herstellung von vitaminpulvern
MX9708416A (es) Derivados de piperazino como antagonistas de neuroquininas.
DE69901519T2 (de) Verfahren zur Herstellung von 2,2'-bis (Hydroxymethyl)alkansäure
WO2001081298A3 (en) Cyclic carboxylic acids as integrin antagonists
ATE339423T1 (de) Verfahren zur herstellung von 4'-o-substituierten 4'-demethyl-1 desoxypodophyllotoxinderivaten und geometrischen isomeren davon ,und antikrebspräparat, das diese enthält
MX337902B (es) Metodos para hacer y utilizar teaflavin, teafavlin-3-galato, teaflavin-3'-galato y teaflavin 3,3´-digalato y mezclas de las mismas.
WO2002074034A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und endothelinantagonisten
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
ATE204294T1 (de) Thiol derivate mit metallopeptidase inhibierender aktivitat
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties